394735-19-4

Basic information

• Product Name: tert-butyl (1-cyclobutyl-3-oxopropan-2-yl)carbaMate
• Synonyms: tert-butyl (1-cyclobutyl-3-oxopropan-2-yl)carbaMate
• CAS NO: 394735-19-4
• Molecular Formula: C₁₂H₂₁NO₃
• Molecular Weight: 227.30004
• Mol File: 394735-19-4.mol
• Article Data: 24

Chemical Properties

• Boiling Point: 329.012°C at 760 mmHg
• Flash Point: 152.781°C
• Appearance: /
• Density: 1.044g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.473
• Storage Temp.: 2-8°C
• CAS DataBase Reference: tert-butyl (1-cyclobutyl-3-oxopropan-2-yl)carbaMate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl (1-cyclobutyl-3-oxopropan-2-yl)carbaMate(394735-19-4)
• EPA Substance Registry System: tert-butyl (1-cyclobutyl-3-oxopropan-2-yl)carbaMate(394735-19-4)

Safety Data

• Hazardous Substances Data: 394735-19-4(Hazardous Substances Data)

Usage

General Description

Tert-butyl (1-cyclobutyl-3-oxopropan-2-yl)carbamate is a chemical compound that belongs to the group of carbamates. It is derived from tert-butyl carbamate and 1-cyclobutyl-3-oxopropan-2-yl. tert-butyl (1-cyclobutyl-3-oxopropan-2-yl)carbaMate is commonly used in organic synthesis and pharmaceutical research as a building block for the preparation of various compounds with potential biological activities. It has a wide range of applications in the field of medicinal chemistry, including as a precursor for the synthesis of new drug candidates and as a tool for the study of enzyme inhibition and mechanism of action. Additionally, it has been investigated for its potential use in the treatment of neurological disorders and cancer.

InChI:InChI=1/C12H21NO3/c1-12(2,3)16-11(15)13-10(8-14)7-9-5-4-6-9/h8-10H,4-7H2,1-3H3,(H,13,15)

Upstream product

• 394735-18-3 tert-butyl 3-cyclobutyl-1-(methoxy(methyl)amino)-1-oxopropan-2-ylcarbamate 
• 565456-75-9 2-(tert-butoxycarbonylamino)-3-cyclobutylpropanoic acid 
• 394735-17-2 ethyl 2-amino-3-cyclobutylpropanoate 
• 816430-02-1 ethyl 2-(tert-butoxycarbonylamino)-3-cyclobutylpropanoate 
• 1025799-39-6 2-(benzhydrylidene-amino)-3-cyclobutyl-propionic acid ethyl ester 
• 17247-58-4 (Bromomethyl)cyclobutane 
• 816429-99-9 SCH 503034D 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 394735-20-7 (2-cyano-1-cyclobutylmethyl-2-hydroxyethyl)carbamic acid tert-butyl ester 
• 394730-60-0 boceprevir 
• 394735-22-9 tert-butyl 4-amino-1-cyclobutyl-3-hydroxy-4-oxobutan-2-ylcarbamate 
• 1036931-36-8 3-amino-4-cyclobutyl-2-hydroxybutanamide hydrochloride 
• 394735-28-5 (1R,2S,5S)-N-(4-amino-1-cyclobutyl-3-hydroxy-4-oxobutan-2-yl)-3-((S)-2-(3-(tert-butyl)ureido)-3,3-dimethylbutanoyl)-6,6-dimethyl-3-azabicylo[3.1.0]-hexane-2-carboxamide 
• 394735-25-2 {(S)-2-[(1R,2S,5S)-2-(2-Carbamoyl-1-cyclobutylmethyl-2-hydroxy-ethylcarbamoyl)-6,6-dimethyl-3-aza-bicyclo[3.1.0]hex-3-yl]-1-cyclohexyl-2-oxo-ethyl}-carbamic acid tert-butyl ester 
• 1373318-77-4 C₇⁽¹³⁾CH₁₆N₂O₂*ClH 

Relevant articles and documents

PROCESS FOR PREPARATION OF BOCEPREVIR AND INTERMEDIATES THEREOF

THE PRESENT INVENTION RELATES TO AN IMPROVED PROCESS FOR THE PREPARATION OF (1R,5S)-N-[3-AMINO-1-(CYCLOBUTYLMETHYL)-2,3-DIOXOPROPYL]-3-[2(S)-[[[(1,1-DIMETHYLETHYL)AMINO]CARBONYL] AMINO]-3,3-DIMETHYL-1-OXOBUTYL]-6,6-DIMETHYL-3-AZABICYCLO[3.1.0]HEXAN-2(S)-CARBOXAMIDE AND ITS INTERMEDIATES

INHIBITORS OF CATHEPSIN B

The present invention is directed to a method of using compounds of Formula (I) to inhibit Cathepsin B. Specifically the compounds of the present invention are useful as therapeutic agents for the treatment of tumor invasion, metastasis, Alzheimer's Disease, arthritis, inflammatory diseases such as chronic and acute pancreatitis, inflammatory airway disease, and bone and joint disorders, including osteoporosis, osteoarthritis, rheumatoid arthritis, psoriasis, and other autoimmune disorders, liver fibrosis, including liver fibrosis associated with HCV, all types of steatosis (including non-alcoholic steatohepatitis) and alcohol-associated steatohepatitis, non-alcoholic fatty liver disease, forms of pulmonary fibrosis including idiopathic pulmonary fibrosis, pathological diagnosis of interstitial pneumonia following lung biopsy, renal fibrosis, cardiac fibrosis, retinal angiogenesis and fibrosis/gliosis in the eye, schleroderma, and systemic sclerosis. The compounds of Formula (I) are also useful for treating subjects with both HCV and fibrosis in a mammal, particularly liver fibrosis, and subjects affirmatively diagnosed or at risk for both HCV and liver fibrosis.

Pharmaceutical formulations and methods of treatment using the same

Pharmaceutical formulations containing at least one compound of Formulae I-XXVI herein and at least one surfactant. Pharmaceutically acceptable carriers and excipients may also be included in the formulations. The formulations of the present invention are suited for use in single unit dosages.